Virax Biolabs Group Limited (VRAX)
VRAX trades on Nasdaq in Health Care, Biotechnology: In Vitro & In Vivo Diagnostic Substances. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$1.74
-6.05% on the day
Market cap
$2.3M
Nano cap
Revenue · 2024
$6K
No prior year to compare
Net income · 2024
-$6.1M
-95739.2% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC 20-F (ifrs-full:RevenueFromContractsWithCustomers), period ending 2025-03-31, https://www.sec.gov/Archives/edgar/data/1885827/000095017025093260/0000950170-25-093260-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLossAttributableToOwnersOfParent), period ending 2025-03-31.
Profile
| Field | Value |
|---|---|
| Ticker | VRAX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Country | United Kingdom |
| IPO year | 2022 |
| SEC CIK | 0001885827 |
| SEC industry code | In Vitro & In Vivo Diagnostic Substances |
| Incorporated in | E9 |
Financials · 2024
| Line | Value |
|---|---|
| Revenue | $6K |
| Net income | -$6.1M |
| Operating income | Not in SEC XBRL data |
| Net margin | -95739.2% |
| Operating margin | Operating income not reported |
| Revenue growth | No prior-year revenue to compare |
| Cash | Not in SEC XBRL data |
| Total assets | Not in SEC XBRL data |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 369.3× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2026-09-10 |
| Latest annual report | 20-F | 2026-07-06 |
| Latest quarterly / interim | 6-K | 2026-10-09 |
Source: SEC EDGAR submissions feed, 157 recent filings. All filings on EDGAR.
Peers in Biotechnology: In Vitro & In Vivo Diagnostic Substances
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| QCLS | Q/C Technologies Inc. | $0.5465 | -5.79% | $4.5M |
| TRIB | Trinity Biotech plc | $6.30 | -3.96% | $5.1M |
| CDIO | Cardio Diagnostics Holdings Inc. | $1.75 | -1.69% | $5.2M |
| VNRX | VolitionRX Limited | $0.1847 | -9.06% | $5.6M |
| BMRA | Biomerica Inc. | $1.85 | +0.82% | $8.5M |
| IMDX | Insight Molecular Diagnostics Inc. | $2.99 | -5.68% | $97.8M |
| ICCC | ImmuCell Corporation | $10.79 | +12.40% | $98.0M |
| MYGN | Myriad Genetics Inc. | $4.08 | -2.86% | $390.3M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier